Accelero Receives GLP Certificate From Competent Authority
Berlin, January 14, 2016
Accelero Bioanalytics is now pleased to provide the 2016 GLP certificate from the competent authority.
Please click here to download the 2016 certificate.
Accelero to Support Aptahem Drug Development Program
To download the press release, please click here.
Berlin, December 17, 2015
Aptahem AB is a biotechnology company based in Sweden which develops a group of patented RNA aptamers. Aptahem´s lead compound APTA-1 is currently being characterized in their preclinical programs.
Accelero Receives Allowance to Analyze Human Infectious Pathogens
The Accelero Team is now pleased to announce the official approval for it´s test facility branch to handle and analyze human infectious pathogens. The written permission to grow and handle microbes like Staphylococcus aureus has been received on 11-MAY-2015, and allows Accelero´s lab team to work on projects in compliance with the German Law on the Prevention and Control of Infectious Diseases (IfSG, Infektionsschutzgesetz).
The permission was granted by the Gesundheitsamt Treptow-Köpenick according to § 49 IfSG, and is valid for safety level S2 projects.
PGP Email Encryption to Protect Clients Projects
The Accelero Team is now proud to provide a 128-bit encryption of all electronic correspondence like emails, and its attachments.
The open source PGP (pretty good privacy) data encryption algorithm is selected to protect all electronical data exchanged with our clients in the course of confidential projects. File attachments like study plans, study reports, intermediate bioanalysis results, etc can also be encrypted, and therefore are only open to recipients who have the personal key of the sender.
If you are interested to learn more on how we respect our customer´s confidentiality needs, please do not hesitate to contact us at any time.
Zencap Completes Crowdfunding for Accelero
More that 52 private investors believe that Accelero Bioanalytics´ competent team has fantastic development potential ...
Accelero Bioanalytics GmbH sets the course for continued sustainable growth. The small startup team is now proud to notice an extreme positive feedback from potential investors for its business model. Accelero will close the current commercial year 2014 also with an annual profit, the third year in a row since the company was kicked off in 2011.